Inovio Pharmaceuticals Inc. [NASDAQ: INO] stock went on a downward path that fall over -3.81% on Tuesday, amounting to a one-week price increase of more than 7.24%. The company report on June 9, 2021 that INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800.
Phase 3 efficacy trial planned to commence this summer in areas of the world underserved by vaccines.
News follows recently announced Phase 2 data, which showed INO-4800 to be well-tolerated and immunogenic in all age groups.
Over the last 12 months, INO stock dropped by -66.14%. The one-year Inovio Pharmaceuticals Inc. stock forecast points to a potential upside of 35.02. The average equity rating for INO stock is currently 2.60, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.74 billion, with 209.40 million shares outstanding and 206.00 million shares in the current float. Compared to the average trading volume of 6.72M shares, INO stock reached a trading volume of 5776619 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Inovio Pharmaceuticals Inc. [INO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INO shares is $13.22 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INO stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Inovio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on June 24, 2021. While these analysts kept the previous recommendation, BofA Securities raised their target price to Neutral. The new note on the price target was released on March 23, 2021, representing the official price target for Inovio Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $35, while Oppenheimer analysts kept a Outperform rating on INO stock.
The Average True Range (ATR) for Inovio Pharmaceuticals Inc. is set at 0.50, with the Price to Sales ratio for INO stock in the period of the last 12 months amounting to 268.02. The Price to Book ratio for the last quarter was 2.99, with the Price to Cash per share for the same quarter was set at 2.56.
INO Stock Performance Analysis:
Inovio Pharmaceuticals Inc. [INO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.24. With this latest performance, INO shares gained by 1.18% in over the last four-week period, additionally sinking by -14.95% over the last 6 months – not to mention a drop of -66.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INO stock in for the last two-week period is set at 51.62, with the RSI for the last a single of trading hit 52.18, and the three-weeks RSI is set at 51.48 for Inovio Pharmaceuticals Inc. [INO]. The present Moving Average for the last 50 days of trading for this stock 8.12, while it was recorded at 8.33 for the last single week of trading, and 9.90 for the last 200 days.
Insight into Inovio Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Inovio Pharmaceuticals Inc. [INO] shares currently have an operating margin of -1760.60. Inovio Pharmaceuticals Inc.’s Net Margin is presently recorded at -2245.39.
Return on Total Capital for INO is now -43.13, given the latest momentum, and Return on Invested Capital for the company is -55.59. Return on Equity for this stock declined to -71.64, with Return on Assets sitting at -47.85. When it comes to the capital structure of this company, Inovio Pharmaceuticals Inc. [INO] has a Total Debt to Total Equity ratio set at 8.47. Additionally, INO Total Debt to Total Capital is recorded at 7.81, with Total Debt to Total Assets ending up at 7.18. Long-Term Debt to Equity for the company is recorded at 7.96, with the Long-Term Debt to Total Capital now at 7.34.
Reflecting on the efficiency of the workforce at the company, Inovio Pharmaceuticals Inc. [INO] managed to generate an average of -$635,157 per employee. Receivables Turnover for the company is 0.70 with a Total Asset Turnover recorded at a value of 0.02.Inovio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.20 and a Current Ratio set at 14.20.
Inovio Pharmaceuticals Inc. [INO] Insider Position Details
There are presently around $644 million, or 36.60% of INO stock, in the hands of institutional investors. The top three institutional holders of INO stocks are: BLACKROCK INC. with ownership of 17,515,053, which is approximately 22.974% of the company’s market cap and around 1.20% of the total institutional ownership; VANGUARD GROUP INC, holding 11,489,304 shares of the stock with an approximate value of $98.69 million in INO stocks shares; and STATE STREET CORP, currently with $70.92 million in INO stock with ownership of nearly -7.184% of the company’s market capitalization.
Positions in Inovio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 121 institutional holders increased their position in Inovio Pharmaceuticals Inc. [NASDAQ:INO] by around 17,596,741 shares. Additionally, 102 investors decreased positions by around 7,024,738 shares, while 39 investors held positions by with 50,329,430 shares. The mentioned changes placed institutional holdings at 74,950,909 shares, according to the latest SEC report filing. INO stock had 36 new institutional investments in for a total of 6,973,688 shares, while 49 institutional investors sold positions of 3,258,725 shares during the same period.